🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hohhot
Clinical trial register · China

Clinical Trials in Hohhot, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca6 Sanofi4 Novartis Pharmaceuticals3 Hoffmann-La Roche2 Peking Union Medical College Hospital2
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Hohhot

59 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Huanghou Zhixie Diwan in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)
NCT07721012Patients With Irritable Bowel Syndrome With Diarrhea
Lei Yunshang Group
Phase 2
120
Beijing, Changsha, Daqing, Guangzhou, Hohhot, Lianyungang, Luoyang, Meihekou
2026-07-31
Recruiting
Mindfulness Intervention for Emotional Distress (MIED) in Patients With GERD
NCT07667894Gastroesophageal Reflux Disease, Emotional Distress
Xinghua Liu
Not applicable
500
Beijing, Baiyin, Shenzhen, Guiyang, Xingtai, Xinle, Chifeng, Hohhot
2026-06-29
Recruiting
A Study of AZD0292 in Chinese Participants With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
NCT07774403Bronchiectasis With Pseudomonas Aeruginosa Colonization
AstraZeneca
Phase 2
84
Anyang, Beijing, Changsha, Chengdu, Chizhou, Haikou, Hefei, Hohhot
2026-06-24
Not yet open
Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
NCT07699770Neuromyelitis Optica Spectrum Disorders (NMOSD), Neuropathic Pain
Tang-Du Hospital
Phase 4
110
Beijing, Chongqing, Harbin, Hohhot, Changchun, Shenyang, Xi'an, Ürümqi
2026-06-15
Recruiting
Effect of the Traditional Chinese Medicine Yufeng Ningxin in Patients With Hypertension
NCT07607275Hypertension, Essential (Primary) Hypertension
Beijing Anzhen Hospital
Phase 4
350
Beijing, Chongqing, Dalian, Hohhot, Longyan, Luohe, Nanchang, Nanjing
2026-05-15
By invitation
A Study on Mucosal Specific IgA Immunokinetics After Administration of Nasal Spray Live Attenuated Influenza Vaccine
NCT07545564Influenza
Changchun BCHT Biotechnology Co.
Phase 4
200
Hohhot
2026-04-09
Recruiting
CAS for Stenosis With High-risk Features for CEA
NCT07370246Carotid Artery Stenosis, Carotid Artery Stenting
Beijing Tiantan Hospital
Not applicable
212
Beijing, Chongqing, Nanning, Guiyang, Shijiazhuang, Xingtai, Wuhan, Hohhot
2026-03-06
Recruiting
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT07363694Moderate to Severe Chronic Obstructive Pulmonary Disease
Pfizer
Phase 2/3
1,156
Chizhou, Fuyang, Hefei, Beijing, Guangzhou, Huizhou, Xinxiang, Hohhot
2026-02-11
Recruiting
SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer
NCT07256236Cervical Cancer
Fujian Cancer Hospital
Phase 2
89
Fuzhou, Zhangzhou, Guangzhou, Nanning, Hohhot, Dalian, Jinan, Jining
2026-01-28
Recruiting
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504Secondary Progressive Multiple Sclerosis (SPMS)
Novartis Pharmaceuticals
Phase 3
1,275
Guangzhou, Zhengzhou, Wuhan, Hohhot, Suzhou, Changchun, Shenyang, Yinchuan
2025-11-11
Recruiting
Real-world Study of Aflibercept 8 mg in nAMD
NCT07640997Neovascular Age-Related Macular Degeneration (nAMD)
Peking University People's Hospital
Observational
300
Beijing, Fuzhou, Shenzhen, Zunyi, Harbin, Nanyang, Wuhan, Hohhot
2025-11-11
Recruiting
Letermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT.
NCT07569653Cytomegalovirus Infections, Cytomegalovirus Disease, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease
WeiShi
Phase 4
120
Beijing, Shijiazhuang, Zhengzhou, Jingzhou, Wuhan, Hohhot, Nanchang, Wenzhou
2025-10-30
Not yet open
PCOT for Outpatients With Acute Respiratory Tract Infection at Risk of Severe Disease in Primary Healthcare
NCT07159230Acute Respiratory Tract Infection
Capital Medical University
Not applicable
16,868
Hohhot
2025-09-15
Recruiting
Safety and Efficacy of TollB-001 Tablets in Moderate to Severe Rheumatoid Arthritis
NCT07408024Rheumatoid Arthritis (RA)
Toll Biotech Co. Ltd. (Beijing)
Phase 2
24
Bengbu, Beijing, Puyang, Hohhot, Pingxiang, Linfen
2025-09-10
Recruiting
A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia
NCT07086976Autoimmune Haemolytic Anaemia
Sanofi
Phase 3
90
Beijing, Chengde, Guangzhou, Hohhot, Nanchang, Suzhou, Tianjin, Wuhan
2025-08-18
Recruiting
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
NCT07088068Type 1 Diabetes Mellitus
Sanofi
Phase 3
723
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hohhot
2025-08-06
Recruiting
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
NCT06911502Follicular Lymphoma
Celgene
Phase 3
400
Beijing, Fuzhou Fujian, Guangzhou, Harbin, Wuhan, Changsha, Hohhot, Suzhou
2025-07-28
Active, closed
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis
NCT07483450Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Hoffmann-La Roche
Phase 4
60
Nanchang, Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hohhot
2025-07-04
Recruiting
Total Energy Expenditure in Healthy Chinese Populations: A Nationwide Study Using the Doubly Labelled Water Method
NCT07178054Healthy
Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences
Observational
240
Chongqing, Shenzhen, Haikou, Hohhot, Shenyang, Qingdao, Tacheng
2025-07-01
Recruiting
The Application of "HUAXI Hole 1" in Reverse-sequence Endoscopic Nipple-sparing Mastectomy With Direct-to-implant Breast Reconstruction
NCT06995118Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Du Zhenggui
Not applicable
337
Fuzhou, Guangzhou, Anyang, Zhengzhou, Changsha, Hohhot, Suzhou, Nanchang
2025-06-17
Recruiting
Effect and Safety of Benzathine Penicillin Combined With Etanercept on Spondyloarthritis
NCT06707194Spondyloarthritis (SpA), Ankylosing Spondylitis (AS)
Nanfang Hospital, Southern Medical University
Phase 4
340
Hefei, Chongqing, Guangzhou, Hohhot, Ganzhou
2025-06-14
Recruiting
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
NCT06977581Asthma
Pfizer
Phase 2
252
Beijing, Guangzhou, Baotou, Hohhot, Najing, Nanjing, Xuzhou, Nanchang
2025-05-20
Recruiting
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
NCT06932263Asthma
AstraZeneca
Phase 2
540
Baotou, Changchun, Chengdu, Chongqing, Guangzhou, Haikou, Hefei, Hohhot
2025-03-26
Active, closed
JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC
NCT06838338Colorectal Cancer
Jian Li
Phase 1
30
Beijing, Hohhot, Shanghai
2025-03-20
Not yet open
Inflammatory and Metabolic Prognostic Assessment in Critically Ill Neurological Patients
NCT06849011Stroke Acute, Encephalitis, Non-traumatic Brain Injury
Yan Zhang
Observational
1,185
Beijing, Lanzhou, Guiyang, Zunyi, Tangshan, Shijiazhuang, Hohhot, Suzhou
2025-03-01
Recruiting
To Evaluate the Safety and Efficacy of a Single-Use IVUS Ablation for Primary Hypertension
NCT07051811Essential Hypertension
Lepu Medical Technology (Beijing) Co., Ltd.
Not applicable
213
Beijing, Chongqing, Xiamen, Lanzhou, Shenzhen, Zhengzhou, Hohhot, Yinchuan
2025-02-25
Active, closed
Efficacy and Safety of OsrhCT and Dimethicone Emulsion Before Upper Endoscopy on Visualization of the Gastric Mucosa.
NCT06722664Gastric Mucosal Lesion
Healthgen Biotechnology Corp.
Phase 2
336
Beijing, Wuhan, Hohhot
2024-12-19
Recruiting
Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer
NCT06926179Lung Cancer (NSCLC), Neoadjuvant Immunotherapy, Radiotherapy, Lung Surgery
Peking University Cancer Hospital & Institute
Observational
500
Beijing, Hohhot, Kunming
2024-12-01
Active, closed
An Observational, Prospective, Multicenter Study to Evaluate the Biologic Use and Outcomes in Chinese Asthma Patients
NCT06605885Asthma
AstraZeneca
Observational
202
Hohhot, Beijing, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Hangzhou
2024-11-14
Recruiting
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
NCT06544499Primary Immune Thrombocytopenia (ITP)
argenx
Phase 3
69
Beijing, Bengbu, Chengde, Hohhot, Huai'an, Huizhou, Tianjin, Wuhan
2024-10-18
By invitation
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma
NCT06609239Asthma
Sanofi
Phase 2
900
Beijing, Changchun, Changsha, Chengde, Guangzhou, Guiyang, Hefei, Hohhot
2024-09-30
Recruiting
POASAC Study (Preoperative Anemia Severity and Classification Study)
NCT06499974Anemia
Peking Union Medical College Hospital
Observational
1,000
Wuhu, Beijing, Zhangzhou, Zunyi, Chifeng, Hohhot
2024-08-02
Recruiting
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
NCT06307665Asthma
AstraZeneca
Phase 3
440
Beijing, Bengbu, Chengdu, Chongqing, Hohhot, Mianyang, Shanghai, Shantou
2024-05-20
Recruiting
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Boehringer Ingelheim
Phase 3
1,700
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Hohhot, Jiaxing
2024-05-06
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Sanofi
Phase 3
2,500
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hohhot
2024-04-16
Active, closed
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT06208150Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
838
Beijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hohhot
2024-01-22
Recruiting
A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population
NCT06419413Asthma
AstraZeneca
Observational
355
Chengdu, Beijing, Changsha, Dongguan, Foshan, Guangzhou, Hainan, Hohhot
2024-01-08
Recruiting
Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia
NCT05998759Connective Tissue Diseases, Thrombocytopenia
Beijing Hospital
Phase 2
296
Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Hohhot, Shenyang
2023-12-02
Active, closed
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome
NCT05946941Sjögren's Syndrome
Bristol-Myers Squibb
Phase 3
774
Beijing, Xiamen, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Changsha, Hohhot
2023-09-11
Recruiting
Treatment Recommendations for Gastrointestinal Cancers Via Large Language Models
NCT06002425Gastrointestinal Neoplasm Malignant
Chinese Academy of Sciences
Not applicable
400
Jiangmen, Zhuhai, Hohhot
2023-08-29
Recruiting
A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma
NCT05954910Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Observational
1,000
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Guiyang, Haikou, Hohhot
2023-08-25
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
NCT06023589Asthma
AstraZeneca
Phase 3
231
Beijing, Changchun, Hohhot, Lanzhou, Nanjing, Shanghai, Shenyang, Shenzhen
2023-08-24
Active, closed
Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)
NCT06009861Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Peking University Hospital of Stomatology
Phase 2
110
Beijing, Baoding, Tangshan, Harbin, Chifeng, Hohhot, Changchun, Shenyang
2023-06-27
Active, closed
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors
NCT05627063Solid Tumor
Abbisko Therapeutics Co, Ltd
Phase 1
169
Chongqing, Luoyang, Zhengzhou, Wuhan, Changsha, Hohhot, Nanchang, Changchun
2023-06-26
Recruiting
A Novel Oral Synbiotic Formula in Reducing Advanced Adenoma Recurrence and Colorectal Neoplasia-related Bacterial Gene Markers
NCT05592886Colorectal Neoplasms, Colorectal Adenoma, Colorectal Cancer, Advanced Adenoma
Chinese University of Hong Kong
Not applicable
649
Hohhot
2022-12-15
Recruiting
Promotion and Application of a New Three-level Etiological Diagnosis Strategy for Fever Clinics in Respiratory Infectious Diseases
NCT05965128Respiratory Infectious Diseases
Huashan Hospital
Observational
1,255
Lanzhou, Harbin, Hohhot, Suzhou, Xuzhou, Shenyang, Jinan, Jining
2022-12-01
Recruiting
Chinese AntiphosPholipid Syndrome cohorT cOllaborative NEtworks
NCT05230017Anti Phospholipid Syndrome
Peking Union Medical College Hospital
Observational
2,000
Beijing, Fuzhou, Guangzhou, Shenzhen, Nanning, Hohhot, Nanjing, Nanchang
2022-10-01
Recruiting
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
NCT05183646FSGS
Dimerix Bioscience Pty Ltd
Phase 3
286
Baotou, Beijing, Chengdu, Guangzhou, Hangzhou, Hohhot, Jinan, Nanchang
2022-05-30
Active, closed
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)
NCT05147220Relapsing Multiple Sclerosis
Novartis Pharmaceuticals
Phase 3
1,000
Guangzhou, Zhengzhou, Changsha, Baotou, Hohhot, Nanchang, Changchun, Beijing
2021-12-16
Active, closed
A Study of NINLARO® in Chinese Adults With Multiple Myeloma
NCT05013190Multiple Myeloma
Takeda
Observational
72
Hefei, Beijing, Zhengzhou, Hohhot, Suzhou, Nanchang, Shenyang, Qingdao
2021-10-29
Active, closed
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05023980Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Loxo Oncology, Inc.
Phase 3
309
Hefei, Beijing, Guangzhou, Wuhan, Changsha, Hohhot, Nanchang, Shenyany
2021-09-23
Recruiting
Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial
NCT04948749ICAD - Intracranial Atherosclerotic Disease, ICAS - Intracranial Atherosclerosis, Drug-eluting Stent, Stroke
Beijing Tiantan Hospital
Not applicable
358
Beijing, Cangzhou, Tangshan, Xingtai, Wuhan, Baotou, Hohhot, Tongliao
2021-07-02
Active, closed
Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)
NCT04765657Hypercholesterolemia
Novartis Pharmaceuticals
Phase 3
345
Lanzhou, Foshan, Guangzhou, Shijiazhuang, Baotou, Hohhot, Nanjing, Nantong
2021-03-01
Active, closed
A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease
NCT04540497IgG4 Related Disease
Amgen
Phase 3
135
Hohhot, Beijing, Guandong, Shang’ai, Shenyang, Wuhan
2020-12-04
Recruiting
Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma
NCT04078230Intrahepatic Cholangiocarcinoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
168
Beijing, Guangzhou, Changsha, Hohhot, Shanghai, Xi’an, Chengdu, Hanzhou
2020-01-01
Recruiting
A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer
NCT06195228Advanced Thyroid Cancer Patients Who Received Target Therapy
Fudan University
Phase 4
800
Fuzhou, Zhengzhou, Wuhan, Hohhot, Shanghai, Shanxi, Hangzhou, Beijing
2020-01-01
Recruiting
Effects of Prior Induced Termination of Pregnancy on Complications and Pregnancy Outcomes.
NCT04183829Reproductive Health, Abortion
National Research Institute for Family Planning, China
Observational
20,000
Zhongshan, Zhangjiakou, Daqing, Changzhou, Yangzhou, Hohhot, Qingdao, Zaozhuang
2019-06-01
Recruiting
Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
NCT06950697Lung Cancer, Venous Thromboembolism, Arterial Thromboembolism, Immune Checkpoint Inhibitors (ICIs)
Beijing Chao Yang Hospital
Observational
2,400
Zhengzhou, Hohhot, Beijing
2019-01-01
Active, closed
Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients
NCT02221999Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Ductal Breast Cancer, Inflammatory Breast Cancer
RenJi Hospital
Phase 2/3
250
Shenzhen, Handan, Hengyang, Hohhot, Kunshan, Yinchuan, Shanghai, Zhoushan
2013-09
Rows per page Showing 1–59 of 59
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/hohhot

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 59 of those studies with a site in Hohhot.

How many clinical trials are recruiting in Hohhot?

38 of the 59 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 4 have not yet opened recruitment, 15 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hohhot), 59 studies
PhaseStudiesRecruitingShare
Phase 316927.1%
Observational131022%
Phase 210616.9%
Not applicable9815.3%
Phase 47411.9%
Phase 1203.4%
Phase 2/3213.4%

Most active sponsors

Lead sponsors with the most studies (Hohhot)
Lead sponsorStudiesRecruiting
AstraZeneca65
Sanofi42
Novartis Pharmaceuticals31
Beijing Tiantan Hospital22
Hoffmann-La Roche21
Peking Union Medical College Hospital22
Pfizer22
Abbisko Therapeutics Co, Ltd10
Amgen10
argenx11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.